UK markets close in 4 hours 45 minutes

Transgene SA (TNG.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
2.4950+0.0300 (+1.22%)
As of 12:15PM CEST. Market open.
Full screen
Previous close2.4650
Open2.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4400 - 2.5000
52-week range1.1820 - 3.1500
Volume20,387
Avg. volume94,114
Market cap243.939M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings date22 Sept 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002

    STRASBOURG, France, September 16, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology (ESMO) virtual meeting taking place from September 16-21, 2021.

  • Business Wire

    Transgene Announces Upcoming Investor Meetings

    STRASBOURG, France, September 13, 2021--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in the upcoming investor events set out below:

  • Business Wire

    Transgene Participates in New Cancer Research Consortium

    STRASBOURG, France & UTRECHT, The Netherlands, September 01, 2021--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.